Is Thymosin Alpha-1 Legal in Florida? How to Access It Legally

Print or save as PDF

Key numbers

  • 1.6 mgDose in the Italian Zadaxin label, which is not a US-approved doseSource: fda.gov, as cited Nov 7, 2026
  • 10 randomized trialsRandomized trials pooled in the 2026 Cochrane review, which found uncertain benefitSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 4 yes and 17 noFDA advisory committee vote against adding thymosin alpha-1 to the state-licensed pharmacy listSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / None - no US application for thymosin alpha-1 [1]
  • Orphan designations / Four in the US, which is not an approval [1]
  • Approved abroad / Italy, India and Hong Kong; Zadaxin is the brand [1]
  • FDA pharmacy list / In none of the three categories for state-licensed pharmacies [2]
  • Advisory committee / 4 yes, 17 no on both the free base and the acetate, December 2024 [3]
  • FDA safety concerns / Immunogenicity for certain routes, peptide impurities, inadequate safety data [4]
  • HHS peptide draft / Not among the six peptides covered [5]
  • WADA / Not named on the 2026 Prohibited List [6]

Is thymosin alpha-1 FDA-approved?

No. A Drugs@FDA search found no US application for it, and FDA's December 2024 review notes four US orphan drug designations, which is a separate process from approval and not an approval [1].

It is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract, and thymalfasin is the synthetic version with the same sequence. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US [1].

Some countries do license it. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

Can a US pharmacy compound it?

Federal compounding rules differ by type of facility. State-licensed pharmacies generally must compound on receipt of a valid patient-specific prescription to avoid FDA's approval requirements; outsourcing facilities may also fill orders that are not for an identified patient [7]. Thymosin alpha-1 appears in none of the three categories on FDA's list for state-licensed pharmacies; on the list for outsourcing facilities it is category 3, 'nominated without adequate support', and FDA's category 1 policy does not apply to it [2][8].

FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) lists it in the 'nominated but withdrawn' table: it had been in category 2 and came off when the nominators withdrew. The concerns FDA posted remain - 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [4].

On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed that it not be added to its list for state-licensed pharmacies [3]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].

Questions worth asking

Choose the questions you want to keep

What this means for Florida

There is no US-approved thymosin alpha-1 product, so there is no approved version to prescribe in Florida or anywhere else in the country [1]. No FDA or HHS action identified allows compounding it [5]. These federal findings do not establish a legal route to obtain it in Florida.

What does the label say, and does it work?

No US-approved dose exists. The Italian Zadaxin label says 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second, and says not for children and contraindicated in pregnancy and breastfeeding [1].

A 2026 Cochrane review pooled 10 randomized trials with 1,349 adults with chronic hepatitis B. It found uncertain benefits, with certainty varying by outcome, and the reviewers said they are 'not sure' thymosin alpha-1 helps [9].

Is thymosin alpha-1 legal in Florida?
There is no FDA-approved thymosin alpha-1 product, and it appears in no category on FDA's list for state-licensed pharmacies [1][2]. No FDA or HHS action identified allows it to be compounded [5], and these federal findings do not establish whether, or by what route, it can be obtained in Florida.
Can I get a compounded thymosin alpha-1 prescription?
State-licensed pharmacies generally need a valid patient-specific prescription to compound; outsourcing facilities may also fill orders that are not for an identified patient [7]. Thymosin alpha-1 appears in none of the three categories on FDA's list for state-licensed pharmacies, and for outsourcing facilities it is category 3, 'nominated without adequate support' [2][8].
Where is thymosin alpha-1 approved?
Italy, as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency has only an orphan designation for hepatocellular carcinoma [1].
What dose of thymosin alpha-1 is used?
No US-approved dose exists [1]. The Italian Zadaxin label says 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12 [1].
Is thymosin alpha-1 banned in sport?
It is not named on WADA's 2026 Prohibited List. WADA does name thymosin beta-4 and derivatives such as TB-500 in S2.3, which is a different peptide [6].
What safety data exist for thymosin alpha-1?
FDA's April 2024 search found zero reports in its adverse-event database [1]. In a 2026 Cochrane review, thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [9]. FDA still posts immunogenicity and peptide-impurity concerns for compounded material [4].
Show all 9 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Florida? How to Access It Legally